泰格医药 reported revenue of ¥3.71B for the period ended 2026-06-30, +14.1% year on year. Net income was ¥-0.19B, a -5.0% net margin on a 27.5% gross margin. The largest revenue line is 临床试验相关服务及实验室服务 at 50% of the total. Free cash flow for the period was ¥0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥3.71B | +14.1% |
| Gross profit | ¥1.02B | — |
| Operating income | ¥-0.08B | — |
| Net income | ¥-0.19B | -151.1% |
| Gross margin | 27.5% | Net margin -5.0% |
| Revenue Q/Q | +5.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 临床试验相关服务及实验室服务 | ¥1.84B | 49.7% |
| 临床试验技术服务 | ¥1.77B | 47.8% |
| 其他(补充) | ¥0.09B | 2.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥2.69B | 72.5% |
| R&D | ¥0.14B | 3.8% |
| SG&A | ¥0.46B | 12.5% |
| Tax & other | ¥0.11B | 2.9% |
| Item | Amount |
|---|---|
| Total assets | ¥27.89B |
| Total liabilities | ¥4.80B |
| Shareholders' equity | ¥23.09B |
| Equity / assets | 82.8% |
| Operating cash flow | ¥0.11B |
| Capital expenditure | ¥0.06B |
| Free cash flow | ¥0.05B |
| Cash conversion (OCF / net income) | -230% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
长亮科技 ・ 金卡智能 ・ 华鹏飞 ・ 永贵电器 ・ ST信源 ・ 东土科技 ・ 东华测试 ・ 蒙草生态 ・ 我武生物 ・ 楚天科技 ・ 全通教育 ・ 炬华科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies